Clinical Trial Update: Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension [Phase 2]

View source ↗

Summary

A Phase 2 dose-response study of AL-37807 ophthalmic solution in open-angle glaucoma or ocular hypertension has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• AL-37807 ophthalmic solution

Snippet

Sponsor: Alcon Research | Conditions: Open-Angle Glaucoma, Ocular Hypertension | Phase 2 | Status: COMPLETED